Piper Sandler raised the firm’s price target on Tactile Systems (TCMD) to $20 from $14 and keeps a Neutral rating on the shares. The firm notes the company posted Q3 top-line results that beat estimates, driven by good performance in both the Lymphedema and AffloVest businesses. Tactile increased its full year 2025 guidance by $6.5M at the midpoint to $317M-$321M as strength in the AffloVest business is expected to continue and as the lymphedema business is benefiting from increased productivity from a larger sales force. However, Piper wrestles with some of the visibility into the ongoing trends in this business after two consecutive guide downs to start the year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCMD:
- Tactile Systems price target raised to $32 from $23.50 at Lake Street
- Strong Buy Recommendation for Tactile Systems Technology: Promising Growth and Strategic Initiatives Drive Confidence
- Tactile Systems upgraded to Buy from Neutral at BTIG
- Tactile Systems Technology Reports Strong Q3 2025 Results
- Tactile Systems reports Q3 EPS 36c, consensus 20c